Compare MONDELEZ INTERNATIONAL INC Common Stock (MDLZ) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MONDELEZ INTERNATIONAL INC Common Stock vs Mesoblast Limited — how do they compare? MONDELEZ INTERNATIONAL INC Common Stock trades at $63.53 (market cap $79.36B), while Mesoblast Limited trades at $16.5 (market cap $2.20B). The key difference: MONDELEZ INTERNATIONAL INC Common Stock is far larger — about 36.1× Mesoblast Limited's market cap, and MONDELEZ INTERNATIONAL INC Common Stock pays a 3.22% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MDLZ | MESO | |
|---|---|---|
Market Cap | $79.36B | $2.20B |
Sector | Consumer Staples | Technology |
52-Week High | $64.99 | $20.96 |
52-Week Low | $51.51 | $12.88 |
Enterprise Value | $99.70B | $2.20B |
Dividend Yield | 3.22% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MDLZ trades at $63.53, up 2.83% today, with a bullish technical outlook supported by moving averages and a consensus price target of $70.50. The company reported Q2 2026 EPS of $0.73, beating estimates, and maintains strong profitability with a net margin of 8.86%. Recent news highlights brand innovation and emerging market growth.
The stock presents a favorable risk-reward profile with analyst support and solid fundamentals, though valuation multiples are elevated. Key risks include reliance on international sales and margin pressures from inflation. Upside is driven by consistent earnings beats and strategic brand initiatives.
MESO trades at $16.78, down 0.83% on the day, with a bullish technical signal from moving averages but bearish oscillators. The company shows strong revenue growth with Ryoncil generating $115 million in its first full year, though it remains unprofitable with a -144.33% net income margin. Recent developments include achieving Phase 3 trial targets for chronic back pain and securing a $50 million non-dilutive facility.
MESO presents a high-risk, high-reward opportunity with significant commercial traction but persistent losses. The bullish analyst consensus and recent regulatory progress support upside potential, though profitability concerns and high P/S ratio of 30.52 warrant caution for risk-averse investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MONDELEZ INTERNATIONAL INC Common Stock
Mondelez has operated as an independent organization since its split from the former Kraft Foods North American grocery business in October 2012. The firm is a leading player in the global snack arena with a presence in the biscuit (47% of sales), chocolate (32%), gum/candy (10%), beverage (4%), and cheese and grocery (7%) aisles. Mondelez's portfolio includes well-known brands like Oreo, Chips Ahoy, Halls, Trident, and Cadbury, among others. The firm derives around one third of revenue from developing markets, nearly 40% from Europe, and the remainder from North America.
Read more on MDLZ →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
